醫(yī)藥生技產(chǎn)業(yè)發(fā)展現(xiàn)況與趨勢(shì)(ppt61)(508mb)-展示頁(yè)
2025-01-07 00:13本頁(yè)面
【正文】 (人體臨床試驗(yàn) )量產(chǎn)IND NDA上市快速篩選藥物來(lái)源藥物改質(zhì)藥物動(dòng)力製造生產(chǎn)臨床試驗(yàn)用藥品代工CROCMO藥理實(shí)驗(yàn)毒理實(shí)驗(yàn)試驗(yàn)用動(dòng)物先導(dǎo)工廠代理商行 銷(xiāo)生物資訊化學(xué)合成Target Validated Target LeadBPODrug Discovery Drug Development 上市後鑑測(cè)BPO： 業(yè)務(wù)流程外包 (Business Process Outsourcing) 資料來(lái)源：生技中心 ITIS計(jì)畫(huà)整理11二 、 現(xiàn)況12Biotech Index(BTK) outperforms NASDAQ DJIA for the past decade13Significant capital flows into biotech/medical device sectors since 202314WORLDWIDE GLOBAL PHARMACEUTICAL SALES15全球藥品市場(chǎng)16Burrill Public Biotech Companies 2023 to 20231 ($billions)2023 2023 2023 2023 2023 2023 % CHANGE20232023Sales/Revenue $ $ $ $ $ $ %RD Expense %Net Ine (loss) () () () () () () %Cash Equivalents 2 %Market Capitalization 382 224 344 400 490 492 %Number of Companies 356 329 315 356 363 360 %1 Includes ADRs2 Includes marketable securitiesSource: Burrill Company17The mapping of the human genome and advances that make it faster and easier to screen potential drug candidates Should be lighting a fire under drug development, but they haven’t so far.July 30, 2023. Business Week18學(xué)名藥 (Generics)與生物相似性藥(Biosimilar/ Followon Biologics)市場(chǎng)19暢銷(xiāo)藥物專利到期公司 產(chǎn)品 主要適應(yīng)癥 2023年銷(xiāo)售額 專利到期Pfizer Zoloft 憂鬱癥 33 2023Norvasc 高血壓 47 2023Zithromax and Zmax 細(xì)菌感染 20 2023Lipitor 降膽固醇 130 2023Zyrtec/Cirrus 過(guò)敏性鼻炎 23 2023Merck Co. Zocor 降膽固醇 44 2023Fosamax 骨質(zhì)疏鬆癥 32 2023AstraZeneca Nexium 胃潰瘍 46 2023ToprolXL/Seloken 高血壓 17 2023Eli Lilly Zyprexa 精神分裂癥 42 2023GlaxoSmith Kline Flonase/Flixonase 過(guò)敏性鼻炎 12 2023Coreg 高血壓 10 2023Advair/Seretide 氣喘 55 2023Lamictal 癲癇 15 2023Lmitrex/Imigran 偏頭痛 13 2023BristolMyers Squibb Pravachol 降膽固醇 23 2023Plavix/Iscover 動(dòng)脈硬化癥 63 2023Novartis Lotrel 高血壓 11 2023SanofiAventis Ambien/Stilnox 失眠 19 2023Lovenox/Clexane 血栓 27 2023Allegra/Telfast 過(guò)敏性鼻炎 17 2023** 億元美金20全球主要生技藥品市場(chǎng)與專利到期時(shí)間產(chǎn)品名稱 製造廠商 *市場(chǎng) (美金億元 ) 專利到期年 Genzyme 2023 Genzyme 2023 A(Interferone a2b) ScheringPlough 2023(insulin) Eli Lilly 2023(Somatropin) Genentech 2023(Interferone a2b) Biogen 2023(Epoetin?) Amgen 2023(Sermorelin) Serono 2023 Abbott 2023(Alterplase) Genentech 2023(Somatrem) Genentech 2023(Filgrastim) Amgen 2023合計(jì) 資料來(lái)源 :Datamonitor。 工研院 IED/IT IS計(jì)劃整理 (2023/10)21我國(guó)製葯產(chǎn)業(yè)現(xiàn)況 1070億元臺(tái)幣 (2023年 )， 其中國(guó)資葯廠銷(xiāo)售額約 270億元
公司管理相關(guān)推薦
鄂ICP備17016276號(hào)-1